Pricing
  1. JP-listed companies
  3. Financials
  4. Income before tax

【JP:4597】

Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025-897-54.26%
Dec 31, 2024-1,961+72.78%
Dec 31, 2023-1,135-54.45%
Dec 31, 2022-2,492+2.05%
Dec 31, 2021-2,442-41.28%
Dec 31, 2020-4,159+131.44%
Dec 31, 2019-1,797-26.50%
Dec 31, 2018-2,445+140.58%
Dec 31, 2017-1,016+105.46%
Dec 31, 2016-495-30.41%
Dec 31, 2015-711+1.25%
Dec 31, 2014-702-20.12%
Dec 31, 2013-879+51.24%
Dec 31, 2012-581

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)